A review on the antagonist Ebola: A prophylactic approach

Biomed Pharmacother. 2017 Dec:96:1513-1526. doi: 10.1016/j.biopha.2017.11.103. Epub 2017 Dec 6.

Abstract

Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual's life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interacts with the immune system of the host which led to understand how the virus functions and effects immune system behaviour. This article presents an exhaustive review on Ebola research which includes EVD illness, symptoms, transmission patterns, patho-physiology conditions, development of antiviral agents and vaccines, resilient health system, dynamics and mathematical model of EBOV, challenges and prospects for future studies.

Keywords: Ebola hemorrhagic fever; Ebola virus; Ebola virus disease; Resilient healthcare system.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use*
  • Disease Outbreaks
  • Ebolavirus / drug effects*
  • Hemorrhagic Fever, Ebola / drug therapy*
  • Hemorrhagic Fever, Ebola / immunology
  • Hemorrhagic Fever, Ebola / prevention & control
  • Humans
  • Vaccines / immunology

Substances

  • Antiviral Agents
  • Vaccines